[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Annexon Inc (ANNX)

Annexon Inc (ANNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 930,628
  • Shares Outstanding, K 163,843
  • Annual Sales, $ 0 K
  • Annual Income, $ -206,690 K
  • EBIT $ -205 M
  • EBITDA $ -203 M
  • 60-Month Beta 1.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.52

Options Overview Details

View History
  • Implied Volatility 311.53% (+86.56%)
  • Historical Volatility 57.66%
  • IV Percentile 92%
  • IV Rank 23.14%
  • IV High 1,118.29% on 03/30/26
  • IV Low 68.58% on 01/22/26
  • Expected Move (DTE 3) 1.88 (34.53%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 241
  • Volume Avg (30-Day) 307
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 20,683
  • Open Int (30-Day) 19,574
  • Expected Range 3.56 to 7.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.26
  • Number of Estimates 4
  • High Estimate $-0.23
  • Low Estimate $-0.29
  • Prior Year $-0.34
  • Growth Rate Est. (year over year) +23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.28 +3.03%
on 05/07/26
6.61 -17.76%
on 04/17/26
-0.41 (-7.01%)
since 04/10/26
3-Month
4.78 +13.81%
on 02/23/26
6.61 -17.76%
on 04/17/26
+0.25 (+4.82%)
since 02/12/26
52-Week
1.67 +225.75%
on 05/14/25
7.18 -24.23%
on 01/23/26
+3.67 (+207.34%)
since 05/12/25

Most Recent Stories

More News
Annexon: The Cash Runway Question Looms Larger Than the Pipeline Update

Barchart Research What to Expect from ANNX Earnings ANNX Generated May 8, 2026 Current Price $5.69 EPS Estimate $$-0.29 Consensus Rating Strong Buy Average Move 5.14% Annexon: The Cash Runway Question...

ANNX : 5.44 (-4.23%)
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026, with Potential to Redefine Vision Preservation in GA Tanruprubart EU Marketing Authorization...

ANNX : 5.44 (-4.23%)
Annexon to Present at the Bank of America Securities Health Care Conference 2026

BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 5.44 (-4.23%)
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference

BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 5.44 (-4.23%)
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with...

ANNX : 5.44 (-4.23%)
Annexon Has Been Quietly Building Toward This Moment. Investors Are About to Find Out If It Was Enough.

Barchart Research What to Expect from ANNX Earnings ANNX Generated March 27, 2026 Current Price $5.00 EPS Estimate $-0.32 Consensus Rating Strong Buy Average Move 5.49% Annexon Has Been Quietly Building...

ANNX : 5.44 (-4.23%)
Annexon Has Been Quietly Building Toward This Moment. Investors Are About to Find Out If It Was Enough.

Barchart Research What to Expect from ANNX Earnings ANNX Generated March 27, 2026 Current Price $5.00 EPS Estimate $-0.32 Consensus Rating Strong Buy Average Move 5.49% Annexon Has Been Quietly Building...

ANNX : 5.44 (-4.23%)
Annexon Has Been Quietly Building Toward This Moment. Investors Are About to Find Out If It Was Enough.

Barchart Research What to Expect from ANNX Earnings ANNX Generated March 27, 2026 Current Price $5.00 EPS Estimate $-0.32 Consensus Rating Strong Buy Average Move 5.49% Annexon Has Been Quietly Building...

ANNX : 5.44 (-4.23%)
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 5.44 (-4.23%)
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory...

ANNX : 5.44 (-4.23%)

Business Summary

Annexon Inc. is a clinical-stage biopharmaceutical company. It engages in developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company's product candidate includes ANX005 and ANX007, which are in clinical stage. Annexon Inc....

See More

Key Turning Points

3rd Resistance Point 5.74
2nd Resistance Point 5.68
1st Resistance Point 5.56
Last Price 5.44
1st Support Level 5.38
2nd Support Level 5.32
3rd Support Level 5.20

See More

52-Week High 7.18
Last Price 5.44
Fibonacci 61.8% 5.08
Fibonacci 50% 4.42
Fibonacci 38.2% 3.77
52-Week Low 1.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.